Celyad completes 30-day safety follow-up of first patient in NKG2D Phase I trial
11 June 2015 | By Victoria White
Celyad has completed the 30-day safety follow-up of the first patient enrolled in a Phase I clinical trial evaluating the safety of NKG2D CAR T-cell therapy..